Bioethics News

South Africa to Try Japanese Drug Against Resistant Form of TB

March 24, 2017

(Reuters) – South Africa launched a new drug program to treat multidrug-resistant tuberculosis (TB) on Friday in a bid to combat the leading cause of natural deaths in Africa’s most industrialized economy. The Health Department said it will run a clinical research program for the drug Delamanid, made by Japan’s Otsuka Holdings Co Ltd, involving 400 patients over the next two years.“Resistance is very minimal to it. The added advantage of this drug is it is more tolerable,” Health Minister Aaron Motsoaledi told a briefing for World TB Day in Johannesburg.

Source: Bioethics.com.

This article was originally published on Bioethics.com under a Creative Commons License.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.